Tarceva is an oral, once-daily, reversible inhibitor of the EGFR signalling pathway. It is indicated as monotherapy for the treatment of patients with advanced non-small cell lung cancer whose tumours are driven by common EGFR gene-activating mutations. It is also indicated for patients with advanced pancreatic cancer in combination with chemotherapy.

Tarceva is available in the US, EU, Japan and more than 100 countries worldwide.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

you go to an external page